GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. stock price has declined significantly over the past six months and year. In July 2024, GeoVax announced an award to advance the development of GEO-CM04S1 in a Phase 2b clinical trial. In November 2024, Alliance Global Partners initiated coverage of GeoVax Labs with a "Buy" recommendation, with an average one-year price target from analysts suggesting a significant upside.

Specific seasonal patterns or demand seasonality for GeoVax Labs, Inc.'s products and services are not detailed in the search results. Demand might be influenced by disease outbreaks or public health initiatives rather than typical consumer seasonality. Detailed seasonal trends require further access.

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing human vaccines and immunotherapies, operating within the Health Technology sector. The company utilizes a Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. Its major product candidates include GEO-CM04S1, a COVID-19 vaccine in Phase 2 clinical trials; Gedeptin, an oncolytic solid tumor gene-directed therapy; GEO-MVA, a vaccine targeting Mpox and smallpox; preventive vaccines against infectious diseases; and therapeutic vaccines for HIV, Hepatitis B, and solid tumor cancers. GeoVax collaborates with entities such as the National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, and the Burnet Institute.

GeoVax Labs, Inc. is headquartered in Smyrna, Georgia, United States, and operates and develops its vaccines and immunotherapies within the United States.

GeoVax Labs has a consensus rating of "Moderate Buy" from Wall Street analysts. The company's average analyst rating score is 2.50, and it scored higher than 54% to 58% of companies evaluated by MarketBeat in the medical sector. Positive clinical program trajectories, favorable regulatory feedback, and expanded collaboration efforts contribute to a positive perception within the biotechnology community.

GeoVax Labs, Inc. has institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of approximately 1,942,930 shares (as of September 30, 2025) or 552,388 shares (as of October 31, 2025). Institutional investors own 6.09% of GeoVax Labs' stock, while insiders hold 0.57%. Major institutional owners include Sabby Management, Llc, Armistice Capital, Llc, and Vanguard Group Inc.